阿司匹林、阿托伐他汀与尼可地尔三联辅助治疗SARS-CoV-2感染住院患者的随机开放标签试验方案
该试验为单中心、前瞻性、双臂平行、开放标签、随机对照优效性试验,计划纳入396例SARS-CoV-2感染伴肺炎但无ARDS的住院患者,1:1随机接受阿司匹林、阿托伐他汀和尼可地尔联合标准治疗或仅标准治疗,主要结局为院内死亡率。
要点
- 三联方案针对炎症、免疫失调、凝血病和内皮功能障碍多个病理环节。
- 纳入标准为>18岁、RT-PCR/RAT阳性、肺炎但无ARDS且需住院者。
- 主要结局为院内死亡率,次要结局包括进展至ARDS、休克、AKI等。
核心结论
- 该试验旨在评估阿司匹林、阿托伐他汀和尼可地尔三联辅助治疗能否降低SARS-CoV-2感染住院患者的院内死亡率。
研究设计与样本
- 单中心、前瞻性、双臂平行设计、开放标签、随机对照优效性试验,计划随机化396例患者,每组198例。
- 纳入>18岁、RT-PCR/RAT阳性、有肺炎但无ARDS表现且需住院的SARS-CoV-2感染患者。
- 采用计算机生成的区组随机化,按1:1比例分为活性干预组A(阿司匹林、阿托伐他汀、尼可地尔联合常规治疗)和对照组B(仅常规治疗)。
关键数值与推荐
- 干预组阿托伐他汀起始剂量40 mg,随后40 mg口服每日一次,用10天或至出院(以较晚者为准)。
- 阿司匹林起始剂量325 mg,随后75 mg每日一次,用10天或至出院(以较晚者为准)。
- 尼可地尔起始剂量10 mg,随后5 mg每日两次,用10天或至出院(以较晚者为准)。
- 主要结局为院内死亡率;次要结局包括进展至ARDS、休克、急性肾损伤、意识障碍、住院时长、机械通气时长及血清标志物(CRP、D-二聚体、S铁蛋白)变化。
- 安全性终点包括肝毒性(ALT/AST > 3倍ULN;高胆红素血症)、肌痛、肌炎(CK 3-10倍ULN)、横纹肌溶解(CK显著大于10倍ULN伴肌酐升高)等。
临床怎么用
- 该方案为COVID-19住院患者提供了一种针对炎症、血栓和内皮功能的联合辅助治疗研究框架。
- 试验采用开放标签设计,结果解读需考虑非盲法可能引入的偏倚。
局限性
- 单中心、开放标签设计可能影响结局评估的客观性。
- 排除标准较多(如ARDS、休克、急性肾衰竭、ACS、脓毒症等),限制了结果外推至重症患者。
- 样本量396例,主要结局为院内死亡率,可能不足以检测次要结局的组间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The pathophysiology of SARS-Cov-2 is characterized by inflammation, immune dysregulation, coagulopathy, and endothelial dysfunction. No single therapeutic agent can target all these pathophysiologic substrates. Moreover, the current therapies are not fully effective in reducing mortality in moderate and severe disease. Hence, we aim to evaluate the combination of drugs (aspirin, atorvastatin, and nicorandil) with anti-inflammatory, antithrombotic, immunomodulatory, and vasodilator properties as adjuvant therapy in covid- 19. TRIAL DESIGN: Single-centre, prospective, two-arm parallel design, open-label randomized control superiority trial. PARTICIPANTS: The study will be conducted at the covid centre of Dr. Rajendra Prasad Government Medical College Tanda Kangra, Himachal Pradesh, India. All SARS-CoV-2 infected patients requiring admission to the study centre will be screened for the trial. All patients >18years who are RT-PCR/RAT positive for SARS-CoV-2 infection with pneumonia but without ARDS at presentation (presence of clinical features of dyspnoea hypoxia, fever, cough, spo2 <94% on room air and respiratory rate >24/minute) requiring hospital admission and consenting to participate in the trial will be included. Patients with documented significant liver disease/dysfunction (AST/ALT > 240), myopathy and rhabdomyolysis (CPK > 5x normal), allergy or intolerance to statins, allergy or intolerance to aspirin, patients taking medications with significant interaction with statins, prior statin use (within 30 days), prior aspirin use (within 30 days), history of active GI bleeding in past three months, coagulopathy, thrombocytopenia (platelet count < 100000/ dl), pregnancy, active breastfeeding, patient unable to take oral or nasogastric medications, patients in altered mental status, shock, acute renal failure, acute coronary syndrome, sepsis and ARDS at presentation will be excluded. INTERVENTION AND COMPARATOR: After randomization, participants in the intervention group will receive aspirin, atorvastatin, and nicorandil (Fig. 1). Atorvastatin will be prescribed as 40 mg starting dose followed by 40 mg oral tablets once daily for ten days or till hospital discharge whichever is later. Aspirin dose will be 325 starting dose followed by 75 mg once daily for ten days or till hospital discharge whichever is later. Nicorandil will be given as 10 mg starting dose followed by 5mg twice daily ten days or till hospital discharge whichever is later. All patients in the intervention and control group will receive a standard of care for covid management as per national guidelines. All patients will receive symptomatic treatment with antipyretics, adequate hydration, anticoagulation with low molecular weight heparin, intravenous remdesivir, corticosteroids (intravenous dexamethasone for 5 days or more duration if oxygen requirement increasing or inflammatory markers are raised), and oxygen support. Patients will receive treatment for comorbid conditions as per guidelines. Fig. 1 Schematic study design MAIN OUTCOMES: The patients will be followed up for outcomes during the hospital stay or for ten days whichever is longer. The primary outcome will be in-hospital mortality. Any progression to ARDS, shock, acute kidney injury, impaired consciousness, length of hospital stay, length of mechanical ventilation (invasive plus non-invasive) will be secondary outcomes. Changes in serum markers (CRP, D -dimer, S ferritin) will be other secondary outcomes. The safety endpoints will be hepatotoxicity (ALT/AST > 3x ULN; hyperbilirubinemia), myalgia-muscle ache, or weakness without creatine kinase (CK) elevation, myositis-muscle symptoms with increased CK levels (3-10) ULN, rhabdomyolysis-muscle symptoms with marked CK elevation (typically substantially greater than 10 times the upper limit of normal [ULN]) and with creatinine elevation (usually with brown urine and urinary myoglobin) observed during the hospital stay. RANDOMIZATION: Computer-generated block randomization will be used to randomize the participants in a 1:1 ratio to the active intervention group A (Aspirin, Atorvastatin, Nicorandil) plus conventional therapy and control group B conventional therapy only. BLINDING (MASKING): The study will be an open-label trial. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): A total of 396 patients will participate in this study, which is randomly divided with 198 participants in each group. TRIAL STATUS: The first version of the protocol was approved by the institutional ethical committee on 1st February 2021, IEC /006/2021. The recruitment started on 8/4/2021 and will continue until 08/07/2021. A total of 281 patients have been enrolled till 21/5/2021. TRIAL REGISTRATION: The trial has been prospectively registered in Clinical Trial Registry - India (ICMR- NIMS): CTRI/2021/04/032648 [Registered on: 8 April 2021]. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol. The study protocol has been reported under the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines.
引用
- Sharma A, Sharma C, Raina S, et al. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial. Trials. 2021. PMID: 34266452. doi:10.1186/s13063-021-05361-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。